|MDACC Study No:||2012-0392 (clinicaltrials.gov NCT No: NCT01576666)|
|Title:||A Phase Ib, Multi-Center, Open Label, Dose Escalation Study of Oral LDE225 in Combination with BKM120 in Patients with Advanced Solid Tumors|
|Principal Investigator:||Marta Penas-Prado|
|Treatment Agent:||BKM120; LDE225|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of LDE225 that can be given in combination with BKM120 in patients with
glioblastoma. The safety of the drug combination will also be studied.
LDE225 and BKM120 are designed to block certain proteins that are important to
the growth and division of cancer cells, which may cause the cells to die.